



Uscom Limited
ABN 35 091 028 090
Suite 1, Level 7, 10 Loftus Street
Sydney NSW 2000 Australia
T +612 9247 4144 F +612 9247 8157
www.uscom.com.au

MARKET ANNOUNCEMENT

New study – 55% of all China mortality from cardiorespiratory disease

Sydney, Australia: Thursday, 17 September 2015: Uscom (ASX code: UCM) (the **Company** or **Uscom**), a revenue stage, medical technology company specialising in cardiac, vascular and pulmonary monitoring devices, has announced to market the findings of a new study demonstrating that approximately 1.6m deaths each year in China are related to pollution induced cardiac, vascular and pulmonary disease and 55% of all deaths are caused by cardiorespiratory disease.

Summary:

- Pollution associated with heart, lung and vessel disease
- Pollution in China responsible for;
 - o 17% of all deaths (all deaths 9.8m per year)
 - o 4,000 deaths per day (1.6m per year)
- Cardiorespiratory causes responsible for 55% of all China mortality (42% for USA)
- Uscom manufactures practice leading cardiorespiratory monitoring technologies (USCOM 1A, Uscom BP+, and Thor Spirometry)
- Uscom sales to China set to grow
- Uscom Thor devices are specialized for monitoring asthma and COPD*

The study was authored by Robert Rohde and Robert Muller from The University of California, Berkeley, USA, and was based on newly released Chinese air monitoring figures. The study used WHO models, real air measurements and computed projections to calculate heart, lung and stroke deaths for different pollutants.

Uscom CEO, Associate Professor Rob Phillips said, *“These data are astonishing and further emphasise the underlying value of our gold standard technologies, and particularly the newly acquired Thor products. Our mission has been to develop, manufacture and market practice leading non-invasive cardiovascular and respiratory devices, to detect and monitor major global diseases. The acquisition of the Thor suite of pulmonary devices, specialised for detection and monitoring of asthma and COPD was a timely expansion of our clinical reach, and with one death every four minutes from COPD in the US and a recent FDA approval for Thor products we are well positioned to significantly contribute to the improved management of these increasing, critical and common diseases.*

I am currently in Fuzhou city talking with Chinese Doctors and distributors about Uscom products. Uscom has established commercial and educational relationships in China with annual sales growth for 2016 projected to be more than 50%.

These new data confirm the Uscom growth strategy as the Uscom BP+ comes on line and the Thor products are adopted as standard home care monitors of asthma and COPD and the sensors of choice for a new era in tele-monitoring. Discussions are ongoing for distribution of the Thor devices in the Chinese and US markets.”

The new suite of Thor digital spirometry devices will slipstream Uscom’s flagship USCOM 1A and Uscom BP+ products and expand Uscom technology into practice leading positions in cardiac, vascular and pulmonary applications.

Reference: Rohde RA, Muller RA. Air Pollution in China: Mapping of Concentrations and Sources. Published 20 Aug 2015 | PLOS ONE, 10.1371/journal.pone.0135749

* COPD – Chronic obstructive pulmonary disease

**Uscom Limited**

ABN 35 091 028 090

Suite 1, Level 7, 10 Loftus Street

Sydney NSW 2000 Australia

T +612 9247 4144 F +612 9247 8157

www.uscom.com.au

MARKET ANNOUNCEMENT

About Uscom

Uscom Limited (UCM) is an ASX listed cardiovascular medical device company. Uscom is an innovative developer and manufacturer of premium cardiovascular devices and has two practice leading technologies in the field of cardiovascular monitoring, the USCOM 1A and the Uscom BP+. Both devices are clinically validated with FDA, CE and TGA regulatory registration, and are currently being marketed into global distribution networks.

The USCOM 1A is a simple, cost-effective and non-invasive device that measures heart function, detects circulatory abnormalities and guides treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, heart failure, and for the guidance of fluid therapy.

The Uscom BP+ is a supra systolic Central Blood Pressure monitor and replaces older and more widespread sub systolic Blood Pressure monitoring technologies focused on arm measurements. Central Blood Pressure is emerging as the new standard of care in hypertension and heart failure. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and arterial pulse pressure waveforms, measures otherwise only available by cardiac catheterisation. The Uscom BP+ is simple to use and measures from a familiar upper arm cuff, and requires no complex training, and has applications in cardiology, intensive care, general practice and home care.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Assoc. Professor Rob Phillips
Executive Chairman
rob@uscom.com.au

Catherine Officer
Company Secretary
secretary@uscom.com.au